Antiangiogenic Effects of Ziyuglycoside II, a Major Active Compound of Sanguisorba officinalis L

Ziyuglycoside II, a major bioactive compound of Sanguisorba officinalis L., displays anticancer potential against several human cancer cells. However, little information concerning its antiangiogenic properties and possible mechanisms is available. The aim of this study was to investigate the inhibi...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2017-09, Vol.31 (9), p.1449-1456
Main Authors: Nam, Sang‐Hyeon, Lkhagvasuren, Khaliunaa, Seo, Hee Won, Kim, Jin‐Kyung
Format: Article
Language:English
Subjects:
Angiogenesis
Angiogenesis Inhibitors - pharmacology
Animals
Antiangiogenics
Anticancer properties
Antitumor activity
Aorta
Aorta - drug effects
Bioactive compounds
Biocompatibility
Cancer
Cell proliferation
Endothelial cells
fibroblast growth factor receptor
Fibroblast growth factors
Growth factors
Hemoglobin
human umbilical vein endothelial cells
Human Umbilical Vein Endothelial Cells - drug effects
Humans
In Vitro Techniques
Male
Mice
Mice, Inbred C57BL
Neovascularization, Pathologic - drug therapy
Plugs
Rats, Sprague-Dawley
Receptor, Fibroblast Growth Factor, Type 1 - metabolism
Rodents
Sanguisorba - chemistry
Saponins - pharmacology
Signal transduction
Signal Transduction - drug effects
Umbilical vein
Vascular endothelial growth factor
vascular endothelial growth factor receptor
Vascular Endothelial Growth Factor Receptor-2 - metabolism
Vascular endothelial growth factor receptors
Vascularization
ziyuglycoside II
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ziyuglycoside II, a major bioactive compound of Sanguisorba officinalis L., displays anticancer potential against several human cancer cells. However, little information concerning its antiangiogenic properties and possible mechanisms is available. The aim of this study was to investigate the inhibitory effects of ziyuglycoside II on angiogenesis. Ziyuglycoside II inhibited the proliferation, migration, and tubule formation of human umbilical vein endothelial cells, as well as the number of microvessels growing from the aortic rings. The underlying antiangiogenic mechanism of ziyuglycoside II correlated with blocking vascular endothelial growth factor receptor‐2 and the fibroblast growth factor receptor‐1 mediated signaling pathway. Moreover, an in vivo Matrigel plug assay in mice showed a significant decrease in vascularization and hemoglobin content in the plugs from ziyuglycoside II‐treated mice compared with control mice. Overall, these results suggest that ziyuglycoside II inhibits various attributes of angiogenesis, which might contribute to its reported antitumor effects. Copyright © 2017 John Wiley & Sons, Ltd.
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.5874